Searchable abstracts of presentations at key conferences in endocrinology

ea0041ep736 | Neuroendocrinology | ECE2016

The medical treatment with pasireotide in Cushing’s disease: an Italian multicenter experience based on “Real Word Evidence”

Pivonello Rosario , Arnaldi Giorgio , Scaroni Carla Maria , Giordano Carla , Cannavo Salvatore , Iacuaniello Davide , Trementino Laura , Zilio Marialuisa , Guarnotta Valentina , Albani Adriana , Cozzolino Alessia , Michetti Grazia , Boscaro Marco , Colao Annamaria

A recent phase III clinical trial has demonstrated that the treatment with the somatostatin analogue pasireotide normalizes cortisol secretion in 15–28% of patients with Cushing’s disease (CD). The aim of the current study was to evaluate the effectiveness of 6-months pasireotide treatment on clinical and hormonal profiles in a group of CD patients with mild to moderate disease according with the real-word evidence. Thirty-two patients with CD unsuccessfully treated ...

ea0037ep810 | Pituitary: clinical | ECE2015

Pasireotide long-acting release maintains biochemical control in patients with acromegaly: results from the extension of randomised, Phase III, PAOLA study

Colao Anna Maria , Bronstein Marcello D , Brue Thierry , Coculescu Mihail , Marinis Laura De , Fleseriu Maria , Guitelman Mirtha A , Pronin Vyacheslav , Raverot Gerald , Shimon Ilan , Fleck Juergen , Kandra Albert , Pedroncelli Alberto M , Gadelha Monica R

Introduction: The PAOLA study in patients with inadequately-controlled acromegaly (n=198) demonstrated superior efficacy of pasireotide long-acting release (LAR; 40 mg/60 mg) in biochemical control (GH <2.5 μg/l and normalized IGF-1) vs continued treatment with octreotide LAR 30 mg/lanreotide Autogel 120 mg (15.4% and 20.0% vs 0%). Here we report preliminary data from the extension phase of PAOLA at wk28.Methods: Pasireotide-LAR (40 mg/...

ea0035p62 | Adrenal Medulla | ECE2014

Expression of IGF/mTOR pathway components in human pheochromocytomas and in vitro inhibition of PC12 rat pheochromocytoma cell growth by mTOR inhibitors alone and in combination with the dual IGFI-R/INS-R antagonist OSI-906

Martino Maria Cristina De , Feelders Richard A. , Dogan Fadime , Koetsveld Peter M. van , Krijger Ronald R. De , Janssen Joseph A M J L , Sprij-Mooij Diana , Lamberts Steven W. J. , Herder Wouter W de , Colao Annamaria , Pivonello Rosario , Hofland Leo J

The mTOR and IGF pathways have been suggested to play a role in the pathogenesis of pheochromocytomas (PCC). mTOR inhibitors, as sirolimus (S) and everolimus (E), as well as IGF1R antagonists could be a potential novel treatment for malignant PPC.The aim of this study was to evaluate the expression of the main components of the IGF/mTOR pathway in human PCC and to investigate the effects of the mTOR inhibitors S and E and of the IGF1R/insulin receptor (I...

ea0035p128 | Calcium and Vitamin D metabolism | ECE2014

Cinacalcet hydrochloride more efficiently controls serum calcium levels in mild-asymptomatic primary hyperparathyroidism without surgery criteria, as compared with surgical cases

Marotta Vincenzo , di Somma Carolina , Rubino Manila , del Prete Michela , Marciello Francesca , Ramundo Valeria , Sciammarella Concetta , Buonomano Pasqualina , Carratu Annachiara , de Luca di Roseto Chiara , Colao Annamaria , Faggiano Antongiulio

Context: Primary hyperparathyroidism (PHPT) is a common endocrine disease, characterized by the chronic elevation of serum calcium (Ca) levels induced by a long-standing increase of PTH concentrations. PHPT includes mild-asymptomatic and symptomatic forms. Cinacalcet is effective in lowering serum Ca levels in PHPT, but is indicated solely in mild-asymptomatic PHPT meeting surgery criteria. Management of non-surgical mild-asymptomatic PHPT is still a debated issue.<p class...

ea0035p907 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Pasireotide LAR demonstrates superior efficacy versus octreotide LAR and lanreotide ATG in patients with inadequately controlled acromegaly: results from a phase III, multicentre, randomized study (PAOLA)

Gadelha Monica , Bronstein Marcello , Brue Thierry , Coculescu Mihail , Fleseriu Maria , Guitelman Mirtha , Pronin Vyacheslav , Raverot Gerald , Shimon Ilan , Lievre Kayo Kodama , Fleck Juergen , Aout Mounir , Pedroncelli Alberto , Colao Annamaria

Background: Some patients with acromegaly do not achieve biochemical control despite receiving maximum-approved doses of currently available somatostatin analogues. This 24-week, randomized study assessed the multireceptor-targeted somatostatin analogue pasireotide LAR vs octreotide LAR/lanreotide Autogel in patients with inadequately controlled acromegaly.Methods: Eligible patients: ≥18 years with mean GH levels ≥2.5 μg/l and IGF1 level...

ea0070aep5 | Adrenal and Cardiovascular Endocrinology | ECE2020

Cytochrome P450 (CYP) 2W1 affect steroid secretion in adrenocortical cell line and tumor tissues

Altieri Barbara , Sbiera Silviu , Weigand Isabel , Volante Marco , Steinhauer Sonja , Lorey Antonia , Kendl Sabine , Kurlbaum Max , Herterich Sabine , Della Casa Silvia , Colao Annamaria , Terzolo Massimo , Kroiss Matthias , Fassnacht Martin , Ronchi Cristina

Background: The human cytochrome P450 (CYP) 2W1 is involved in the metabolism of several endogenous substrates, including lysophospholipids and fatty acids. Using a polyclonal antibody, we previously demonstrated a high CYP2W1 immunoreactivity in adrenocortical tumors, particularly in those secreting steroids. The aim of the study was to better elucidate the relationship between CYP2W1 and steroid secretion in adrenocortical carcinoma (ACC) H295R cell line and in a larger seri...

ea0070aep530 | Endocrine-related Cancer | ECE2020

Reversal effect of Vitamin D (VitD) on exosome-mediated everolimus resistance (EveR) in hepatocellular carcinoma (HCC) cell line: A molecular study

Gentile Annalisa , Negri Mariarosaria , Montò Tatiana , Patalano Roberta , de Angelis Cristina , Simeoli Chiara , Ferrigno Rosario , Cristina De Martino Maria , Simona Auriemma Renata , Colao Annamaria , Pivonello Rosario , Pivonello Claudia

Cancer exosomes emerged as important mediators of cancer drug resistance. Drug exposure-mediated EveR in HCC cell lines can be reversed by VitD pre- and co-treatment. The current study aimed to investigate whether cancer exosomes from EveR HCC cell line are able to induce EveR in parental cells and whether VitD may activate reversal effect on exosome-mediated EveR.To this purpose, parental JHH-6 and EveR JHH-6 cell line were used. The uptakeof exosomes, ...

ea0070aep744 | Pituitary and Neuroendocrinology | ECE2020

Pasireotide-induced hyperglycemia and efficacy of antidiabetic treatments in patients with acromegaly: Evaluation of two referral centers

F.S. Grasso Ludovica , Chiloiro Sabrina , Pirchio Rosa , Giampietro Antonella , Auriemma Renata S. , Bianchi Antonio , De Martino Maria Cristina , Negri Mariarosaria , Colao Annamaria , Pontecorvi Alfredo , De Marinis Laura , Pivonello Rosario

Pasireotide (PAS) has a safety profile similar to first-generationsomatostatin analogues (SSA), except for a higher frequency of hyperglycaemia-related adverse events (AEs). However, consensus on the best management of PAS-induced hyperglycaemia in acromegalic patients has still to be defined. The current study aims at investigating the effects of long-term PAS treatment on glucose metabolism, by evaluating the clinical management of hyperglycemia-relatedAEs in acromegalic pat...

ea0032s21.2 | Multi-centre pituitary studies | ECE2013

Lessons from the Liège Acromegaly Survey (LAS)

Petrossians Patrick , Zacharieva Sabina , Chanson Philippe , Neggers Sebastian , Brue Thierry , Colao Annamaria , Hulting Anna-Lena , Delemer Brigitte , Hana Vaclav , Stalla Gunter , Minuto Francesco , Jaffrain-Rea Marie-Lise , Carvalho Davide , Montanana Carmen Fajardo , Beckers Albert

The Liège Acromegaly Survey is a cross-sectional study on acromegalic patients, developed as an in-house tool in Liège, then extended to other Europeans participating centers. The database differentiates itself from national and multinational registries by adopting a goal oriented approach and it was conceived following a list of open questions on acromegaly. After an initial test run in Liège, the database installation started on mid-March 2010. Thirteen other ...

ea0032p518 | Endocrine tumours and neoplasia | ECE2013

Neuroendocrine tumours (NETs) of lung: new data on atypical carcinoid and large cell neuroendocrine carcinoma from a French-Italian multicentric study

Marciello Francesca , Mercier Olaf , Ferolla Piero , David Planchard , Filosso Pier Luigi , Chapelier Alain , Grimaldi Franco , de Latour Bertrand Richard , Blanco Giusy , Guigay Joel , Monaco Guglielmo , Dartevelle Philippe , Papotti Mauro , Scoazec Jean-Yves , Colao Annamaria , Baudin Eric , Faggiano Antongiulio

Introduction: Natural history of lung neuroendocrine tumours (NETs) and in particular of two histological subtypes, atypical carcinoid (AC) and large cell neuroendocrine carcinoma (LCNEC), is poorly known.Aim of the study was to determine disease-free survival (DFS) and overall survival (OS) of sporadic, resectable, non-metastatic lung AC and LNEC.Patients and methods: This retrospective study involved 116 consecutive patients surg...